Halozyme Lands Largest Enhanze Deal To Date With Bristol

Bristol will pay $105m up front and as much as $1.76bn in milestone fees to use the Enhanze technology in drugs against up to 11 immuno-oncology targets. Also, Roche will pay up to $190m to add a target to an existing partnership.